Purification, characterization, and immunogenicity of a disulfide cross-linked Plasmodium vivax vaccine candidate antigen, merozoite surface protein 1, expressed in Escherichia coli

Infection and Immunity

Volumn 69, Issue 9, 2001, Pages 5464-5470

  Dutta, S ^a   Ware, L A ^a   Barbosa, A ^a   Ockenhouse, C F ^a   Lanar, D E ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLUTATHIONE; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; INTERLEUKIN 10; INTERLEUKIN 4; MEROZOITE SURFACE PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; THIOREDOXIN REDUCTASE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PURIFICATION; ARTICLE; CELL PROLIFERATION; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS LINKING; ESCHERICHIA COLI; FEMALE; GENE MUTATION; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; PLASMODIUM VIVAX; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, PROTOZOAN; CROSS-LINKING REAGENTS; DISULFIDES; ESCHERICHIA COLI; LYMPHOCYTE ACTIVATION; MALARIA VACCINES; MALARIA, VIVAX; MANNITOL; MEROZOITE SURFACE PROTEIN 1; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; OLEIC ACIDS; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; VACCINATION; VACCINES, SYNTHETIC;

EID: 0034868615     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.69.9.5464-5470.2001     Document Type: Article

References (30)

1. Drug resistance among malaria and other parasites
2. Efficient folding of proteins with multiple disulfide bonds in the Escherichia coli cytoplasm
3. Expression of the 19-kilodalton carboxy-terminal fragment of the Plasmodium falciparum merozoite surface protein-1 in Escherichia coli as a correctly folded protein
4. Protective immunity against Plasmodium yoelii malaria induced by immunization with particulate blood-stage antigens
5. The crystal structure of C-terminal merozoite surface protein 1 at 1.8 A resolution, a highly protective malaria vaccine candidate
6. 19) of Plasmodium vivax in Saimiri boliviensis monkeys
7. Merozoite surface antigen-1 of Plasmodium
8. Apparent lack of N-glycosylation in the asexual intraerythrocytic stage of Plasmodium falciparum
9. Expression, purification and characterization of a functional region of the Plasmodium vivax Duffy binding protein
10. Characterization of human T- and B-cell epitopes in the C terminus of Plasmodium falciparum merozoite surface protein 1: Evidence for poor T-cell recognition of polypeptides with numerous disulfide bonds
11. Tissue sulfhydryl groups
12. Structure and expression of the gene for Pv200, a major blood-stage surface antigen of Plasmodium vivax
13. The potential for recruiting immune responses toward type 1 or type 2 T cell help
14. Antibodies to malaria vaccine candidates pvs25 and pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes
15. Expression and immunogenicity of the C terminus of a major blood-stage surface protein of Plasmodium vivax, Pv200(19), secreted from Saccharomyces cerevisiae
16. High-level expression of Plasmodium vivax apical membrane antigen 1 (AMA-1) in Pichia pastoris: Strong immunogenicity in Macaca mulatta immunized with P. vivax AMA-1 and adjuvant SBAS2
17. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers
18. Advances in refolding of proteins produced in E. coli
19. Immunization against malaria with a recombinant protein
20. The combined epidermal growth factor-like modules of Plasmodium yoelii merozoite surface protein-1 are required for a protective immune response to the parasite
21. Immunity to erythrocytic stages of malarial parasites
22. Plasmodium vivax merozoite surface protein 1 C-terminal recombinant proteins in baculovirus
23. Prolonged expression of IFN-gamma induced by protective blood-stage immunization against Plasmodium yoelii malaria
24. Baculovirus merozoite surface protein 1 C-terminal recombinant antigens are highly protective in a natural primate model for human Plasmodium vivax malaria
25. Immunogenicity of four Plasmodium falciparum preerythrocytic antigens in Aotus lemurinus monkeys
26. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant
27. Genetic restriction and specificity of the immune response in mice to fusion proteins containing repeated sequences of the Plasmodium falciparum antigen Pf155/RESA
28. Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria
29. The role of TH1 and TH2 cells in a rodent malaria infection
30. Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant